Clown Car

[anonymous]

When I checked out, strike that, when I left (checked out years ago), everyone was counting on an AbVie buyout. Is that still THE exit strategy?

 

[anonymous]

U betcha!
The buyout dream is - AbbVie expecting to have a PDUFA date in July for their New Drug Application (NDA) for elagolix in endometriosis-associated pain. If approved, elagolix will be the first new oral medical management treatment option for endometrenosis

 

[anonymous]

U betcha!
The buyout dream is - AbbVie expecting to have a PDUFA date in July for their New Drug Application (NDA) for elagolix in endometriosis-associated pain. If approved, elagolix will be the first new oral medical management treatment option for endometrenosis

What does this have to do with our TD drug promoted to CNS, Abbie doesn’t
even have a CNS division ???

 

[anonymous]

U betcha!
The buyout dream is - AbbVie expecting to have a PDUFA date in July for their New Drug Application (NDA) for elagolix in endometriosis-associated pain. If approved, elagolix will be the first new oral medical management treatment option for endometrenosis

AbbVie couldn't launch a turd into a toilet.

 

[anonymous]

What does this have to do with our TD drug promoted to CNS, Abbie doesn’t
even have a CNS division ???

P.H.A.T bit@h good personality TD = personality

 

[anonymous]

M&A is a wet dream, a delusion fueled by greed. The costs push women to consider surgery over branded drug therapies. The cost of surgery is about the same over 1yr and their share of that cost is less, it's a one time event, doesn't risk bone loss, and many other upsides in comparison to drug treatment. Branded drugs are the 2nd choice among 2nd line treatments.

Piling on to dash the buyout dream are the other "golix" (oral GnRHR antagonists) drugs coming for approval.

 

[anonymous]

M&A is a wet dream, a delusion fueled by greed. The costs push women to consider surgery over branded drug therapies. The cost of surgery is about the same over 1yr and their share of that cost is less, it's a one time event, doesn't risk bone loss, and many other upsides in comparison to drug treatment. Branded drugs are the 2nd choice among 2nd line treatments.

Piling on to dash the buyout dream are the other "golix" (oral GnRHR antagonists) drugs coming for approval.

Sandtock & Rastetter have the inside track to make this happen!

Mar. 21, 2019 3:58 PM•SA Editor Douglas W. House
In an interview on CNBC, a Jefferies analyst said that Biogen (BIIB -29.5%) may now be targeting acquisitions after its aducanumab flop. Attractive candidates include Biohaven Pharmaceutical Holding Company (BHVN+8.2%), Neurocrine Biosciences (NBIX +5.9%), Alder BioPharmaceuticals (ALDR +6.2%), Sage Therapeutics (SAGE +3.6%), ACADIA Pharmaceuticals (ACAD +3.7%) and GW Pharmaceuticals (GWPH +3.3%).

 

[anonymous]

M&A is a wet dream, a delusion fueled by greed. The costs push women to consider surgery over branded drug therapies. The cost of surgery is about the same over 1yr and their share of that cost is less, it's a one time event, doesn't risk bone loss, and many other upsides in comparison to drug treatment. Branded drugs are the 2nd choice among 2nd line treatments.

Piling on to dash the buyout dream are the other "golix" (oral GnRHR antagonists) drugs coming for approval.

Rastetter and Sandrock have the inside track to bring it home

Mar. 21, 2019 3:58 PM -

In an interview on CNBC, a Jefferies analyst said that Biogen (BIIB -29.5%) may now be targeting acquisitions after its aducanumab flop. Attractive candidates include Biohaven Pharmaceutical Holding Company (BHVN+8.2%), Neurocrine Biosciences (NBIX +5.9%), Alder BioPharmaceuticals (ALDR +6.2%), Sage Therapeutics (SAGE +3.6%), ACADIA Pharmaceuticals (ACAD +3.7%) and GW Pharmaceuticals (GWPH +3.3%).

 

[anonymous]

M&A is a wet dream, a delusion fueled by greed. The costs push women to consider surgery over branded drug therapies. The cost of surgery is about the same over 1yr and their share of that cost is less, it's a one time event, doesn't risk bone loss, and many other upsides in comparison to drug treatment. Branded drugs are the 2nd choice among 2nd line treatments.

Piling on to dash the buyout dream are the other "golix" (oral GnRHR antagonists) drugs coming for approval.

This prediction has really held up. DTC for Myfembree shows commitment to the product.